Wedbush analyst Liana Moussatos reiterated a Buy rating on Verona Pharma Plc (VRNA) today and set a price target of $56. The company’s shares opened today at $12.10, close to its 52-week low of $10.16.
According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -8.2% and a 36.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Catabasis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Verona Pharma Plc with a $41 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.55 and a one-year low of $10.16. Currently, Verona Pharma Plc has an average volume of 3,059.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. Verona Pharma’s product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.
